Pain Management Therapeutics Market Size To Hit US$ 105.77 Billion By 2030

The global pain management therapeutics market size is expected to hit around USD 105.77 billion by 2030 and progressing a CAGR of 4.3% over the forecast period 2022 to 2030.

Pain Management Therapeutics Market Size 2022-2030

The on pain management therapeutics Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.

Download Free Sample@ https://www.precedenceresearch.com/sample/1224

Scope of the Report

Report Highlights	Details
Market Size	USD 105.77 Billion by 2030
Growth Rate	CAGR of 4.3% from 2022 to 2030
Base Year	2021
Historic Data	2017 to 2021
Forecast Period	2022 to 2030
Segments Covered	Drug Class, Indication, Distribution Channel
Regional Scope	North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)

A recent report provides crucial insights along with application based and forecast information in the Global Pain management therapeutics Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Pain management therapeutics market.

A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.

Companies and Manufacturers Covered

The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Pain management therapeutics market are included as given below:

Pain management therapeutics Market Key Players

Teva Pharmaceutical
Pfizer
Abbott
Mallinckrodt Pharmaceuticals
Endo International
GlaxoSmithKline
AstraZeneca
Depomed
Merck
Novartis

Market Segments

By Drug Class

NSAIDs
Opioids
Anesthetics
Antidepressants
Anticonvulsants
Others

By Indication

Arthritic Pain
Neuropathic Pain
Chronic Back Pain
Post-Operative Pain
Cancer Pain
Others

By Distribution Channel

Online Pharmacy
Retail Pharmacy
Hospital Pharmacy

By Geography

North America
- - U.S.
  - Canada
Europe
- - Germany
  - France
  - United Kingdom
  - Rest of Europe
Asia Pacific
- - China
  - Japan
  - India
  - Southeast Asia
  - Rest of Asia Pacific
Latin America
- - Brazil
  - Rest of Latin America
Middle East & Africa (MEA)
- - GCC
  - North Africa
  - South Africa
  - Rest of Middle East & Africa

Report Objectives

To define, describe, and forecast the global pain management therapeutics market based on product, and region
To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the pain management therapeutics market

Table of Content

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pain Management Therapeutics Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pain Management Therapeutics Market

5.1. Covid-19: Pain Management Therapeutics Industry Impact
5.2. Pain Management Therapeutics Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pain Management Therapeutics Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pain Management Therapeutics Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Pain Management Therapeutics Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Growing prevalence of chronic disorders
6.1.1.2. Increasing geriatric population
6.1.2. Market Restraints
6.1.2.1. Side-effects associated with some pain management medications
6.1.3. Market Opportunities
6.1.3.1. Growing research and development expenditure
6.1.3.2. Technological advancements

Chapter 7. Global Pain Management Therapeutics Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pain Management Therapeutics Market Revenue by Market Players (2016 -2019)
7.1.1.2. Pain Management Therapeutics Market Revenue Market Share by Market Players (2016 -2019)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Class Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pain Management Therapeutics Market, By Drug Class

8.1. Pain Management Therapeutics Market, by Drug Class, 2017 - 2030
8.1.1. NSAIDs
8.1.1.1. Market Revenue and Forecast (2017 - 2030)
8.1.2. Opioids
8.1.2.1. Market Revenue and Forecast (2017 - 2030)
8.1.3. Anesthetics
8.1.3.1. Market Revenue and Forecast (2017 - 2030)
8.1.4. Antidepressants
8.1.4.1. Market Revenue and Forecast (2017 - 2030)
8.1.5. Anticonvulsants
8.1.5.1. Market Revenue and Forecast (2017 - 2030)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2017 - 2030)

Chapter 9. Global Pain Management Therapeutics Market, By Indication

9.1. Pain Management Therapeutics Market, by Indication, 2017 - 2030
9.1.1. Arthritic Pain
9.1.1.1. Market Revenue and Forecast (2017 - 2030)
9.1.2. Neuropathic Pain
9.1.2.1. Market Revenue and Forecast (2017 - 2030)
9.1.3. Chronic Back Pain
9.1.3.1. Market Revenue and Forecast (2017 - 2030)
9.1.4. Post-Operative Pain
9.1.4.1. Market Revenue and Forecast (2017 - 2030)
9.1.5. Cancer Pain
9.1.5.1. Market Revenue and Forecast (2017 - 2030)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2017 - 2030)

Chapter 10. Global Pain Management Therapeutics Market, By Distribution Channel

10.1. Pain Management Therapeutics Market, by Distribution Channel, 2017 - 2030
10.1.1. Online Pharmacy
10.1.1.1. Market Revenue and Forecast (2017 - 2030)
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast (2017 - 2030)
10.1.3. Hospital Pharmacy
10.1.3.1. Market Revenue and Forecast (2017 - 2030)

Chapter 11. Global Pain Management Therapeutics Market, Regional Estimates and Trend Forecast

11.1. North America
11.1.1. Market Revenue Forecast by Drug Class(2017 - 2030)
11.1.2. Market Revenue Forecast by Indication(2017 - 2030)
11.1.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.1.4. U.S
11.1.4.1. Market Revenue Forecast (2017 - 2030)
11.1.5. Canada
11.1.5.1. Market Revenue Forecast (2017 - 2030)
11.2. Europe
11.2.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.2.2. Market Revenue Forecast by Indication (2017 - 2030)
11.2.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.2.4. UK
11.2.4.1. Market Revenue Forecast (2017 - 2030)
11.2.5. Germany
11.2.5.1. Market Revenue Forecast (2017 - 2030)
11.2.6. France
11.2.6.1. Market Revenue Forecast (2017 - 2030)
11.2.7. Rest of EU
11.2.7.1. Market Revenue Forecast (2017 - 2030)
11.3. Asia Pacific (APAC)
11.3.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.3.2. Market Revenue Forecast by Indication (2017 - 2030)
11.3.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.3.4. China
11.3.4.1. Market Revenue Forecast (2017 - 2030)
11.3.5. India
11.3.5.1. Market Revenue Forecast (2017 - 2030)
11.3.6. Japan
11.3.6.1. Market Revenue Forecast (2017 - 2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue Forecast (2017 - 2030)
11.4. LATAM
11.4.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.4.2. Market Revenue Forecast by Indication (2017 - 2030)
11.4.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.4.4. Brazil
11.4.4.1. Market Revenue Forecast (2017 - 2030)
11.4.5. Rest of LATAM
11.4.5.1. Market Revenue Forecast (2017 - 2030)
11.5. Middle East and Africa (MEA)
11.5.1. Market Revenue Forecast by Drug Class (2017 - 2030)
11.5.2. Market Revenue Forecast by Indication (2017 - 2030)
11.5.3. Market Revenue Forecast by Distribution Channel (2017 - 2030)
11.5.4. GCC
11.5.4.1. Market Revenue Forecast (2017 - 2030)
11.5.5. North Africa
11.5.5.1. Market Revenue Forecast (2017 - 2030)
11.5.6. South Africa
11.5.6.1. Market Revenue Forecast (2017 - 2030)
11.5.7. Rest of MEA
11.5.7.1. Market Revenue Forecast (2017 - 2030)

Chapter 12. Company Profiles

12.1. Teva Pharmaceutical
12.1.1. Company Overview, Business Information, Regional Presence
12.1.2. Product Portfolio Analysis
12.1.2.1. Product Details, Specification, Distribution Channel
12.1.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.1.4. Recent Developments and Strategies
12.2. Pfizer
12.2.1. Company Overview, Business Information, Regional Presence
12.2.2. Product Portfolio Analysis
12.2.2.1. Product Details, Specification, Distribution Channel
12.2.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.2.4. Recent Developments and Strategies
12.3. Abbott
12.3.1. Company Overview, Business Information, Regional Presence
12.3.2. Product Portfolio Analysis
12.3.2.1. Product Details, Specification, Distribution Channel
12.3.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.3.4. Recent Developments and Strategies
12.4. Mallinckrodt Pharmaceuticals
12.4.1. Company Overview, Business Information, Regional Presence
12.4.2. Product Portfolio Analysis
12.4.2.1. Product Details, Specification, Distribution Channel
12.4.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.4.4. Recent Developments and Strategies
12.5. Endo International
12.5.1. Company Overview, Business Information, Regional Presence
12.5.2. Product Portfolio Analysis
12.5.2.1. Product Details, Specification, Distribution Channel
12.5.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.5.4. Recent Developments and Strategies
12.6. GlaxoSmithKline
12.6.1. Company Overview, Business Information, Regional Presence
12.6.2. Product Portfolio Analysis
12.6.2.1. Product Details, Specification, Distribution Channel
12.6.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.6.4. Recent Developments and Strategies
12.7. AstraZeneca
12.7.1. Company Overview, Business Information, Regional Presence
12.7.2. Product Portfolio Analysis
12.7.2.1. Product Details, Specification, Distribution Channel
12.7.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.7.4. Recent Developments and Strategies
12.8. Depomed
12.8.1. Company Overview, Business Information, Regional Presence
12.8.2. Product Portfolio Analysis
12.8.2.1. Product Details, Specification, Distribution Channel
12.8.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.8.4. Recent Developments and Strategies
12.9. Merck
12.9.1. Company Overview, Business Information, Regional Presence
12.9.2. Product Portfolio Analysis
12.9.2.1. Product Details, Specification, Distribution Channel
12.9.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.9.4. Recent Developments and Strategies
12.10. Novartis
12.10.1. Company Overview, Business Information, Regional Presence
12.10.2. Product Portfolio Analysis
12.10.2.1. Product Details, Specification, Distribution Channel
12.10.3. Revenue, Price, and Gross Margin (2017 - 2020)
12.10.4. Recent Developments and Strategies